THERAPEUTICS
ANALONA
Committed to revolutionizing the treatment of solid tumors with innovative new therapies
OUR STORY
Innovating Tomorrow's Solid Tumor Solutions
Founded in 2024, based on our top tier solid tumor research, which has identified a range of novel targets and mechanisms of action.
Analona Therapeutics discover and develop antibody based therapeutics against these targets with an initial focus on a key interactor and facilitator of metabolite transporters.
Our first project aim to develop a first in class tumor specific metabolic disruptor with opportunities across a range of high medical need solid tumors.
OUR TEAM
Meet Our Team
Gert Bolwig
Chief Executive Officer
25 years in pharma/biotech; veteran in drug development (Pre-clinical – Phase III), BD, and fundraising
Axel Behrens
Chief Scientific Officer and Co-founder
Professor, serial entrepreneur and internationally recognized expert in cancer stem cell biology
Foto: Esben Zøllner Olesen for BioInnovation Institute
Mikkel Wandahl Pedersen
Co-founder and Advisor
20 years of experience within biologics drug discovery and development from Symphogen, Servier and Nykode Therapeutics
GET IN TOUCH
